• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Nephros Hires Wes Lobo as Chief Marketing Officer

    2/18/21 7:30:00 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care
    Get the next $NEPH alert in real time by email

    SOUTH ORANGE, NJ, Feb. 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Wes Lobo as Chief Marketing Officer, reporting directly to Nephros Chief Executive Officer, Andy Astor. In this role, Wes will be responsible for driving the company’s strategic growth through innovative solutions, go-to-market strategies, and marketing.

    “Wes brings more than 20 years of expertise in the water business, with broad and deep experience across marketing, strategy, product management, sales, engineering, and leadership,” said Andy Astor.

    Andy continued, “Prior to the COVID-19 pandemic, Nephros leveraged its strong R&D and Sales organizations to grow revenues more than 50% annually for nearly 4 years. We were able to accomplish this without a formal marketing organization. Now, as we emerge from the pandemic and resume our growth trajectory, there is a powerful need to connect more deeply and directly with our customers and to broaden our reach. With his ability to function at both strategic and operational levels, as well as his enthusiasm and sense of purpose, I am confident that Wes is the right person to lead our strategic growth initiatives.”

    Wes joins Nephros after recently serving as Vice President of Marketing and New Product Development at Watts Water Technologies, a leader in plumbing, heating, and water quality products and services for residential, commercial, and general industrial markets.

    On joining Nephros, Wes said, “Nephros is a company founded on industry-leading science and technology for water safety through purification and pathogen detection. It is also a company comprised of a diverse and passionate team dedicated to helping people through education, product solutions, and emergency responses to pathogen outbreaks. I believe the combination of these two attributes positions the company for accelerated growth, as it demonstrated for 15 consecutive quarters prior to the COVID-19 pandemic. I am humbled and honored to be given the opportunity to tell the Nephros story, work with this incredible team, and help unlock the Nephros growth potential.”

    Prior to joining Watts in early 2018, Wes spent 20 years with Xylem and ITT Industries in commercial roles of increasing responsibility covering the domestic and international municipal, industrial, and commercial markets in sales, marketing, business development, strategy, and customer service.

    He holds a Bachelor of Science in Chemical Engineering from Lafayette College and a Master of Business Administration from the Duke University Fuqua School of Business. He is a certified Lean Six Sigma Black Belt and a graduate of the Xylem Executive Development Program.

    About Nephros

    Nephros is a leading water technology company in medical and commercial water purification and pathogen detection, headquartered in the USA. Our diverse team of passionate employees are dedicated to advancing point-of-use water safety through education, product solutions, and emergency outbreak response management.

    For more information about Nephros, please visit www.nephros.com.

    Forward-Looking Statements

    This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the benefits expected from Nephros’s new Chief Marketing Officer and other statements that are not historical facts, including statements accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, the impact of the COVID-19 pandemic, and the availability of financing or other capital when needed. These and other risks and uncertainties are detailed in Nephros’ reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2019. Nephros does not undertake any responsibility to update the forward-looking statements in this release.

    Investor Relations Contact:
    Kirin Smith, President
    PCG Advisory, Inc.
    (646) 823 -8656
    [email protected]

    Company Contact:
    Andy Astor, CEO
    Nephros, Inc.
    (201) 345-0824
    [email protected]


    Get the next $NEPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NEPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEPH
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nephros Inc.

      10-Q - NEPHROS INC (0001196298) (Filer)

      5/15/25 4:00:45 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - NEPHROS INC (0001196298) (Filer)

      5/8/25 4:15:47 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Nephros Inc.

      DEFA14A - NEPHROS INC (0001196298) (Filer)

      4/30/25 4:16:33 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Krandel Judy

      4 - NEPHROS INC (0001196298) (Issuer)

      3/31/25 4:11:30 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Director Amron Arthur H was granted 22,418 shares, increasing direct ownership by 22% to 125,881 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      1/3/25 6:13:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Lask Alisa

      4 - NEPHROS INC (0001196298) (Issuer)

      1/3/25 5:08:03 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Financials

    Live finance-specific insights

    See more
    • Nephros Announces Financial Results for Quarter Ended September 30, 2024

      Third-Quarter Net Revenue of $3.5 Million;Operational Improvements Result In First Profitable Quarter SOUTH ORANGE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024. Financial Highlights* Net income of $0.2 million, compared to a net loss of $0.2 millionAdjusted EBITDA of $295,000, compared to $11,000Net revenue of $3.5 million, an 8% increase over Q2 2024; a decrease of 6% over Q3 prior year *Stated performance is relative to same period in the prior year unless otherwise no

      11/7/24 4:01:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Schedules Third Quarter 2024 Financial Results Conference Call

      SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a repl

      10/31/24 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Announces Financial Results for Quarter Ended June 30, 2024

      Second-Quarter Net Revenue of $3.3 Million; New Accounts Help Drive Growth in Core Programmatic Business SOUTH ORANGE, NJ, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2024. Financial Highlights* Net revenue of $3.3 million, a decrease of 8% over Q2 prior year; programmatic revenue (excluding emergency response revenue) increased 8% over Q2 prior yearNet loss of $0.3 million, compared to a net loss of $0.4 millionAdjusted EBITDA of ($133,000), compared to ($183,000) *Stated performance

      8/8/24 4:01:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nephros to Participate in the Benchmark Company Annual Discovery One-on-One Investor Conference on December 11, 2024 in NYC

      SOUTH ORANGE, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will be participating in the Benchmark Company 13th Annual Discovery One-on-One Investor Conference. The event is scheduled for Wednesday, December 11, 2024, at the New York Athletic Club in New York City. Robert Banks, CEO and Judy Krandel, CFO of Nephros, Inc. will be hosting one-on-one and group investor meetings. If you would like to schedule a 1x1 investor meeting please make sure you are registered here: The conference offers emerging growth and dynamic publicly traded comp

      12/4/24 9:00:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Announces Financial Results for Quarter Ended September 30, 2024

      Third-Quarter Net Revenue of $3.5 Million;Operational Improvements Result In First Profitable Quarter SOUTH ORANGE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024. Financial Highlights* Net income of $0.2 million, compared to a net loss of $0.2 millionAdjusted EBITDA of $295,000, compared to $11,000Net revenue of $3.5 million, an 8% increase over Q2 2024; a decrease of 6% over Q3 prior year *Stated performance is relative to same period in the prior year unless otherwise no

      11/7/24 4:01:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Schedules Third Quarter 2024 Financial Results Conference Call

      SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a repl

      10/31/24 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amron Arthur H bought $11,176 worth of shares (5,000 units at $2.24), increasing direct ownership by 5% to 103,463 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      5/30/24 4:35:22 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Banks Robert R. Jr. bought $112,050 worth of shares (50,000 units at $2.24), increasing direct ownership by 250% to 70,000 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      5/16/24 4:49:44 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Amron Arthur H bought $17,130 worth of shares (7,000 units at $2.45) and acquired 91,463 shares (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      3/14/24 4:28:20 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley FBR initiated coverage on Nephros with a new price target

      B. Riley FBR initiated coverage of Nephros with a rating of Buy and set a new price target of $12.50

      1/26/21 6:12:57 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/3/23 3:15:24 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/3/23 3:13:44 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/3/23 3:11:33 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Nephros Hires Judy Krandel as Chief Financial Officer

      SOUTH ORANGE, NJ, Nov. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the company's finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephros's long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, inv

      11/1/23 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Appoints Joe Harris to Its Board of Directors

      SOUTH ORANGE, NJ, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Joe Harris to its Board of Directors. "We are excited that Joe is joining our board," said Andy Astor, President and Chief Executive Officer of Nephros. "He brings years of financial, sales, and marketing acumen to the board, with experience in both large and small healthcare ventures." "I am thrilled to join the Nephros board," said Joe Harris. "I believe Nephros is at an exciting point as they continue to focus on sales moment

      9/8/22 4:00:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • RION Appoints Alisa Lask as Chief Commercial Officer

      - Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov

      1/14/22 9:00:00 AM ET
      $CLGN
      $NEPH
      Industrial Specialties
      Health Care
      Medical/Dental Instruments